Autism: Comorbidities and Treatment Patterns in the Real World, a Retrospective Cohort Study Among Children, Adolescents and Adults Newly Diagnosed with Autism.
Azza ShoaibM Soledad CepedaGayle MurrayRachel Ochs-RossPublished in: Journal of autism and developmental disorders (2021)
We used real world data to summarize comorbidities and interventions among patients newly diagnosed with autism spectrum disorder (ASD). Data were derived from two claims-based US healthcare databases; Medicaid and Optum to construct a retrospective cohort of 36,000 patients. Attention-Deficit-Hyperactivity-Disorder (ADHD) was the most common co-morbidity (Medicaid: 50.09%; Optum: 44.16%), followed by mood disorder (Medicaid: 16.56% and Optum: 17.47%). Most patients received at least one type of treatment. Behavioral therapy was common (74.64% in Medicaid and 71.97% in Optum). More than half the cohorts received at least 1 pharmacotherapy. However, pharmacotherapies were diverse. Combination therapy and therapy switching was common. Understanding the clinical diversity and complexity of patients with ASD is an important first step in understanding unmet therapeutic needs.
Keyphrases
- newly diagnosed
- attention deficit hyperactivity disorder
- autism spectrum disorder
- combination therapy
- end stage renal disease
- health insurance
- healthcare
- young adults
- intellectual disability
- ejection fraction
- chronic kidney disease
- electronic health record
- affordable care act
- big data
- prognostic factors
- peritoneal dialysis
- machine learning
- social media